Published in Ann Rheum Dis on April 01, 1984
Association of MHC antigens with susceptibility to and severity of rheumatoid arthritis in multicase families. Ann Rheum Dis (1985) 1.07
Immunogenetic markers in rheumatic diseases. Can Fam Physician (1990) 0.75
Perivascular infiltration in normal skin of patients with rheumatoid arthritis: association with rheumatoid factors and HLA-DR antigens. Ann Rheum Dis (1988) 0.75
Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med (1968) 27.34
Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med (1978) 7.97
Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J (1978) 4.29
Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum (1972) 3.43
HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med (1980) 2.52
HLA antigens and rheumatoid arthritis. Association between HLA-DRw4 positivity and IgM rheumatoid factor production. Arthritis Rheum (1980) 1.97
Rheumatoid arthritis and B lymphocyte alloantigen HLA-DRw4. J Rheumatol (1980) 1.41
HLA--Dw4 and rheumatoid arthritis. Tissue Antigens (1979) 1.36
HLA-Dw2 as a marker of resistance against juvenile diabetes mellitus. Tissue Antigens (1978) 0.96
Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med (2001) 7.41
"Lymphokines": non-antibody mediators of cellular immunity generated by lymphocyte activation. Nature (1969) 6.42
Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med (1982) 5.09
Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J (1978) 4.29
Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum (1992) 3.92
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med (1984) 3.31
An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol (1982) 3.05
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
Immunological enhancement of rat kidney grafts. Lancet (1969) 2.73
The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum (1992) 2.68
Statement on the nomenclature of human C4 allotypes. Immunobiology (1983) 2.66
Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet (1980) 2.63
The sensitivity and specificity of reduced CD8 lymphocyte levels in the diagnosis of polymyalgia rheumatica/giant cell arteritis. Clin Exp Rheumatol (1994) 2.61
HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A (1989) 2.60
A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide. J Immunol (1990) 2.55
HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med (1980) 2.52
Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain (1980) 2.36
Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum (1992) 2.31
Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25
Factors influencing the risk of multiple sclerosis developing in patients with optic neuritis. Brain (1978) 2.19
Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol (1984) 2.17
Ankylosing spondylitis, HLA-B27 and Klebsiella. I. Cross-reactivity studies with rabbit antisera. Br J Exp Pathol (1980) 2.16
A role for purine metabolism in the immune response: Adenosine-deaminase activity and deoxyadenosine catabolism. Lancet (1978) 2.15
Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis (1993) 2.01
Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol (1984) 1.95
Histocompatibility antigens, autoantibodies, and immunoglobulins in alcoholic liver disease. Br Med J (1976) 1.91
Enhanced antibody responses in active chronic hepatitis: relation to HLA-B8 and HLA-B12 and porto-systemic shunting. Lancet (1976) 1.89
Failure of long surviving, passively enhanced kidney allografts to provoke T-dependent alloimmunity. I. Retransplantation of (AS X AUG)F1 kidneys into secondary AS recipients. J Exp Med (1979) 1.88
HLA and hepatitis B infection. Lancet (1994) 1.85
B-lymphocyte alloantigens associated with multiple sclerosis. Lancet (1976) 1.73
D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol (1984) 1.69
Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis (1989) 1.68
IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Scand J Rheumatol (1983) 1.67
The significance of the association between HLA and multiple sclerosis. Br Med Bull (1978) 1.65
B lymphocyte alloantigens in the study of the genetic basis of rheumatoid arthritis. Ann Rheum Dis (1977) 1.65
Analysis of T cell subsets in the peripheral blood and synovial fluid of patients with rheumatoid arthritis by means of monoclonal antibodies. Ann Rheum Dis (1983) 1.64
The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol (2001) 1.62
Histocompatibility antigens in diabetic identical twins. Lancet (1975) 1.59
Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol (1993) 1.57
The molecular basis of alloreactivity. Immunol Today (1990) 1.56
Antibodies to intermediate filaments in polymyalgia rheumatica and giant cell arteritis: a sequential study. Ann Rheum Dis (1987) 1.54
Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain (1987) 1.54
Influence of defined incompatibilities and area of burn on skin-homograft survival in burned-subjects. Lancet (1969) 1.52
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol (1995) 1.49
HLA matching and corneal grafting. Lancet (1976) 1.46
Histocompatibility antigens in active chronic hepatitis and primary biliary cirrhosis. Br Med J (1974) 1.45
Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis (1994) 1.44
Speculations on the specificity of suppression. Immunol Today (1989) 1.43
The immune response to allogeneic rat platelets; Ag-B antigens in matrix form lacking Ia. Eur J Immunol (1977) 1.42
Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther (2000) 1.39
Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol (1990) 1.38
Influence of pregnancy on disease activity in a patient with palindromic rheumatism. J Rheumatol (1992) 1.38
The influence of sex upon the antibody response to an incompatible tumour. Immunology (1965) 1.38
ELISA assays for IgM and IgG rheumatoid factors. J Immunol Methods (1982) 1.37
A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry (1987) 1.35
Selective migration of the human helper-inducer memory T cell subset: confirmation by in vivo cellular kinetic studies. Eur J Immunol (1991) 1.34
Phytohaemagglutinin transformation of lymphocytes in burned patients. Transplantation (1971) 1.32
Transformation of lymphocytes from patients awaiting cadaver renal transplants. Lancet (1976) 1.32
Circadian variation in disease activity in rheumatoid arthritis. Br Med J (Clin Res Ed) (1982) 1.30
Human pregnancy serum inhibits interleukin-2 production. Clin Exp Immunol (1984) 1.29
HLA-DRw4 and rheumatoid arthritis. Lancet (1979) 1.29
Matching for HLA in transplantation. Br Med Bull (1978) 1.27
Enhancement of renal allografts in rats and man. Transplant Rev (1972) 1.27
Strong primary selection for the Dw4 subtype of DR4 accounts for the HLA-DQw7 association with Felty's syndrome. Hum Immunol (1991) 1.27
An immunogenetic basis for the tissue involvement in Behçet's syndrome. Immunology (1979) 1.25
Strong association between HLA-DRW2 and antibody-mediated Goodpasture's syndrome. Lancet (1978) 1.23
The uptake of 125I-labeled rat alloantibody and its loss after combination with antigen. Transplantation (1973) 1.23
Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis. Ann Rheum Dis (1983) 1.23
Evidence for the continuous recruitment and activation of T cells into the joints of patients with rheumatoid arthritis. Eur J Immunol (1994) 1.22
Are primary alloresponses truly primary? Int Immunol (1990) 1.21
Influence of HL-A incompatibility on cadaveric renal transplantation. Lancet (1969) 1.21
Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun (2000) 1.21
Disease activity and pregnancy associated alpha 2-glycoprotein in rheumatoid arthritis during pregnancy. Br Med J (Clin Res Ed) (1983) 1.20
Transplantation antigens from human spleens. Nature (1968) 1.20
Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br J Rheumatol (1990) 1.20
The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) (2002) 1.19
Synovial T lymphocyte-specific immune response to Chlamydia trachomatis in Reiter's disease. Arthritis Rheum (1991) 1.19
Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis (1983) 1.19
Activated T lymphocytes of the synovial membrane in rheumatoid arthritis and other arthropathies. Scand J Immunol (1985) 1.19
The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum (1993) 1.19
Rosette inhibition test in severely burned patients. Br Med J (1973) 1.17
Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain (1986) 1.15
Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology (1988) 1.15
HLA antigen frequencies in systemic vasculitis: increase in HLA-DR2 in Wegener's granulomatosis. Arthritis Rheum (1983) 1.15
Sequence analysis of HLA-DR4B1 subtypes: additional first domain variability is detected by oligonucleotide hybridization and nucleotide sequencing. Hum Immunol (1990) 1.14
In vivo analysis of disease modifying drug therapy activity in rheumatoid arthritis by sequential immunohistological analysis of synovial membrane interleukin 1 beta. J Rheumatol (1994) 1.13
Immunological enchancement of human kidney graft. Lancet (1970) 1.12
Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J Rheumatol (1991) 1.12
Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis Rheum (2002) 1.12
Plasma exchange and immunosuppression in the stiff man syndrome. Lancet (1989) 1.12
Linkage of Chido and HL-A. Tissue Antigens (1974) 1.12
Expression of HLA-DR, DQ and DP antigens and interleukin-2 receptor on synovial fluid T lymphocyte subsets in rheumatoid arthritis: evidence for "frustrated" activation. J Rheumatol (1987) 1.11
The arthropathy of cystic fibrosis. Ann Rheum Dis (1988) 1.10